In conclusion, the GRh2-functionalized liposomal platform developed in this study provided a promising strategy for effective BRD4-PROTAC delivery in breast cancer treatment, addressing critical challenges in current targeted therapies through its multifunctional design. Here, BRD4 is linked to breast carcinoma.